Vestnik of the Far East Branch of the Russian Academy of SciencesVestnik of the Far East Branch of the Russian Academy of SciencesВестник Дальневосточного отделения Российской академии наук0869-7698The Russian Academy of Sciences67610910.31857/S0869769824020179lbzlqkChemical SciencesХимические наукиResearch ArticleThe problem of antibioticresistance. Secondary plant metabolites: antibacterial properties and application prospectsПроблема антибиотикорезистентности. Вторичные метаболиты растений: антибактериальные свойства и перспективы примененияhttps://orcid.org/0000-0003-3495-1608YerkinAskar A.ЕркинАскар Арманулы
Russian Federation

Master’s Student

магистрант

askartlegenov12@gmail.comOrenburg State UniversityОренбургский государственный университет15042024219921228022025Copyright ©; 2024, Russian Academy of SciencesCopyright ©; 2024, Российская академия наук2024Russian Academy of SciencesРоссийская академия наукhttps://journals.eco-vector.com/0869-7698/article/view/676109

The review examines the problem of antibiotic resistance in the world and the causes of resistance, as well as a way to overcome this problem. One of the ways to overcome it is the use of secondary metabolites of plants with antibacterial properties. The review includes a large number of studies on the mechanisms of action of the antibacterial properties of secondary metabolites on bacterial cells and the possibility of combining them with various antibiotics to accumulate bactericidal and bacteriostatic effects and overcome the problem of resistance of microorganisms to antibiotics.

Рассматривается проблема антибиотикорезистентности в мире и причины ее возникновения, а также способы преодоления данной проблемы. Одним из способов является применение вторичных метаболитов растений, обладающих антибактериальными свойствами. Работа включает обзор большого количества исследований, посвященных механизмам действия антибактериальных свойств вторичных метаболитов на бактериальные клетки и возможности их комбинирования с различными антибиотиками для аккумулирования бактерицидного и бактериостатического эффекта и преодоления проблемы резистентности микроорганизмов к антибиотикам.

antibiotic resistancesecondary metabolites of plantscombined actionmechanisms of actionreviewsантибиотикорезистентностьвторичные метаболиты растенийкомбинированное действиемеханизмы действияобзорыChristopher J. L., Murray K., Shunji I., Fablina Sh., Swetschinski L., Aguilar G. R., Gray A. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–655.Christopher J. L., Murray K., Shunji I., Fablina Sh., Swetschinski L., Aguilar G. R., Gray A. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis // Lancet. 2022. Vol. 399. P. 629–655.Review on antimicrobial resistance 2016. URL: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (date of application: 09.10.2023).Review on antimicrobial resistance 2016. URL: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (дата обращения: 09.10.2023).Review on antimicrobial resistance 2014. URL: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pd (date of application: 09.10.2023).Review on antimicrobial resistance 2014. URL: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pd (дата обращения: 09.10.2023).Zuk M., Dorotkiewicz-Jach A., Drulis-Kawa Z. Bactericidal activities of GM flax seedcake extract on pathogenic bacteria clinical strains. BMC Biotechnology. 2020;(14):70–75.Zuk M., Dorotkiewicz-Jach A., Drulis-Kawa Z. Bactericidal activities of GM flax seedcake extract on pathogenic bacteria clinical strains. // BMC Biotechnol. 2020. N14. P. 70–75.Antibiotic resistance threats in the United States. US Department of Health and Human Services; US Centers for Disease Control and Prevention. 2019;(12):148–152.Antibiotic resistance threats in the United States / US Department of Health and Human Services; US Centers for Disease Control and Prevention. 2019. N12. P. 148–152.Prestinaci F., Pezzotti P., Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathogens Global Health. 2018;(7):309–318.Prestinaci F., Pezzotti P., Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon // Pathog. Glob. Health. 2018. Vol. 109 (7). P. 309–318.WHO. Global action plan on antimicrobial resistance 2015. URL: https://www.who.int/ru/publications/i/item/9789241509763 (date of application: 10.10.2023).WHO. Global action plan on antimicrobial resistance 2015. URL: https://www.who.int/ru/publications/i/item/9789241509763 (дата обращения: 10.10.2023).Naylor N. R., Atun R., Zhu N. et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrobial Resistance and Infection Control. 2018;(25):7–58.Naylor N. R., Atun R., Zhu N. et al. Estimating the burden of antimicrobial resistance: a systematic literature review // Antimicrob. Resist. Infect. Control. 2018. N25. P. 7–58.CassiniA., Högberg L. D., Plachouras D.et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infectious Diseases. 2019;(1):56–66.CassiniA., Högberg L. D., Plachouras D.et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis // Lancet Infect. Dis. 2019. Vol. 19 (1). P. 56–66.Lim Ch., Takahashi E., Hongsuwan M. et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. Elife. 2016;(5):518–582.Lim Ch., Takahashi E., Hongsuwan M. et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country // Elife. 2016. Vol. 5. P. 518–582.Temkin E., Fallach N., Almagor J. et al. Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study. Lancet Global Health. 2018;6:969–979.Temkin E., Fallach N., Almagor J. et al. Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study // Lancet Glob. Health. 2018. Vol. 6. P. 969–979.Rudd K. E., Johnson S. C., Agesa K. H. et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–211.Rudd K. E., Johnson S. C., Agesa K. H. et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study // Lancet. 2020. Vol. 395. P. 200–211.Ge M., Chen Z., Russell H., Onishi H. R., Kohler J., Silver L. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science. 1999;284(5413):507–511.Ge M., Chen Z., Russell H., Onishi H. R., Kohler J., Silver L. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala // Science. 1999. Vol. 284. P. 507–511.Olaitan A. O. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Frontiers in Microbiology. 2022;(26):605–643.Olaitan A. O. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria // Front. Microbiol. 2022. N26. P. 605–643.Moffatt J. H., Harper M., Harrison P., Hale J. D., Vinogradov E. Colistin resistance in A. baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrobial Agents and Chemotherapy. 2018;(54):4971–4977.Moffatt J. H., Harper M., Harrison P., Hale J. D., Vinogradov E. Colistin resistance in A. baumannii is mediated by complete loss of lipopolysaccharide production // Antimicrob. Agents Chemother. 2018. N54. Р. 4971–4977.Eliopoulos G. M. Quinolone resistance mechanisms in pneumococci. Clinical Infectious Diseases. 2020;(15):350–356.Eliopoulos G. M. Quinolone resistance mechanisms in pneumococci // Clin. Infect. Dis. 2020. N15. P. 350–356. DOI: 10.1086/428052.Hooper D. C., Jacoby G. A. Mechanisms of drug resistance: quinolone resistance. Annals New York Academy Sciences. 2018;1354(1):12–31.Hooper D. C., Jacoby G. A. Mechanisms of drug resistance: quinolone resistance // Ann. N. Y. Acad. Sci. 2018. Vol. 1354. P. 12–31.Jacoby G. A. Mechanisms of resistance to quinolones. Clinical Infectious Diseases. 2005;(15):120–126. DOI: 10.1086/428052.Jacoby G. A. Mechanisms of resistance to quinolones // Clin. Infect. Dis. 2005. N15. P. 120–126.Hooper D. C., Jacoby G. A. Topoisomerase inhibitors: Fluoroquinolone mechanisms of action and resistance. Cold Spring Harbor Perspectives in Medicine. 2016;6(9). a025320.Hooper D. C., Jacoby G. A. Topoisomerase inhibitors: Fluoroquinolone mechanisms of action and resistance // Cold Spring Harb. Perspect. Med. 2016. Vol. 6 (9). a025320.Sheed K. A., Phelan J. E. Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa. Scientific Reports. 2021;11(1):141–194.Sheed K. A., Phelan J. E. Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa // Sci. Rep. 2021. Vol. 11 (1). P. 141–194.Campbell E. A. Structural mechanism for Rifampicin inhibition of bacterial RNA polymerase. Cell. 2022;104(6):901–912.Campbell E. A. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase // Cell. 2022. Vol. 104 (6). Р. 901–912.Koch A., Mizrahi V., Warner D. F. The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from Rifampicin? Emerging Microbes and Infections. 2014;3(3):17–25.Koch A., Mizrahi V., Warner D. F. The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin? // Emerg. Microbes Infect. 2014. Vol. 3 (3). P. 17–25.Zaw M. T., Emran N. A., Lin Z. Mutations inside Rifampicin-resistance determining region of rpoB gene associated with Rifampicin-resistance in Mycobacterium tuberculosis. Journal of Infection and Public Health. 2018;11(5):605–610.Zaw M. T., Emran N. A., Lin Z. Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis // J. Infect. Public. Health. 2018. Vol. 11 (5). P. 605–610.Zampieri M. The genetic underground of antibiotic resistance. Science. 2021;(371):783–784.Zampieri M. The genetic underground of antibiotic resistance // Science. 2021. N371. P. 783–784.Daoud Z., Kourani M., Saab R. et al. Resistance of Streptococcus pneumoniae isolated from Lebanese patients between 2005 and 2009. Revista Espanola de Quimioter. 2020;24(2):84–90.Daoud Z., Kourani M., Saab R. et al. Resistance of Streptococcus pneumoniae isolated from Lebanese patients between 2005 and 2009 // Rev. Esp. Quimioter. 2020. Vol. 24 (2). P. 84–90.Chen H., Wang X., Yin Y. et al. Molecular characteristics of oxazolidinone resistance in enterococci from a multicenter study in China. BMC Microbiology. 2019;19(1):162.Chen H., Wang X., Yin Y. et al. Molecular characteristics of oxazolidinone resistance in enterococci from a multicenter study in China // BMC Microbiol. 2019. Vol. 19 (1). P. 162.Konovalova A., Kahne D., Silhavy Th. Outer Membrane Biogenesis. Annual Review of Microbiology 2017;(71):539–556.Konovalova A., Kahne D., Silhavy Th. Outer membrane biogenesis // Annu. Rev. Microbiol. 2017. N71. P. 539–556.Mickiewicz K. M., Yoshikazu K., Drage L. Possible role of L-form switching in recurrent urinary tract infection. Nature Communication. 2019;10(1).4379.Mickiewicz K. M., Yoshikazu K., Drage L. et al. Possible role of L-form switching in recurrent urinary tract infection // Nat. Com. 2019. Vol. 10 (1). 4379.Greene N. P., Kaplan E., Crow A., Koronakis V. Antibiotic resistance mediated by the MacB ABC transporter family: A structural and functional perspective. Frontiers in Microbiology. 2018;(9):950.Greene N. P., Kaplan E., Crow A., Koronakis V. Antibiotic resistance mediated by the MacB ABC transporter family: A structural and functional perspective // Front. Microbiol. 2018. N9. P. 950.Studemeister A. E., Quinn J. P. Selective imipenem resistance in Pseudomonas aeruginosa associated with diminished outer membrane permeability. Antimicrobial Agents and Chemotherapy. 2018;32(8):1267–1268.Studemeister A. E., Quinn J. P. Selective imipenem resistance in Pseudomonas aeruginosa associated with diminished outer membrane permeability // Antimicrob. Agents Chemother. 2018. Vol. 32 (8). P. 1267–1268.Kornelsen V., Kumar A. Update on multidrug resistance efflux pumps in Acinetobacter spp. Antimicrobial Agents and Chemotherapy. 2021;65(7):514–521.Kornelsen V., Kumar A. Update on multidrug resistance efflux pumps in Acinetobacter spp. // Antimicrob. Agents Chemother. 2021. Vol. 65 (7). P. 514–521.Raskin I., Ribnicky D., Komarnytsky S. et al. S. Plants and human health in the twenty-first century. Trends in Biotechnology. 2002;20(12):522–531.Raskin I., Ribnicky D., Komarnytsky S. et al. Plants and human health in the twenty-first century // Trends Biotechnol. 2002. Vol. 20 (12). P. 522–531.Hikal D. Antibacterial activity of piperine and black pepper oil. Biosciences. Biotechnology Research Asia. 2018;15(4):877–880.Hikal D. Antibacterial activity of piperine and black pepper oil // Biosci. Biotechn. Res. Asia. 2018. Vol. 15 (4). P. 877–880.Khameneh B., Iranshahy M., Ghandadi M. et al. Investigation of the antibacterial activity and efflux pump inhibitory effect of co-loaded piperine and gentamicin nanoliposomes in methicillin-resistant Staphylococcus aureus. Drug Development and Industrial Pharmacy. 2015;41(6):989–994.Khameneh B., Iranshahy M., Ghandadi M. et al. Investigation of the antibacterial activity and efflux pump inhibitory effect of co-loaded piperine and gentamicin nanoliposomes in methicillin-resistant Staphylococcus aureus // Drug Dev. Ind. Pharm. 2015. Vol. 41 (6). P. 989–994.Mgbeahuruike E. E. et al. Antimicrobial and synergistic effects of commercial piperine and piperlongumine in combination with conventional antimicrobials. Antibiotics (Basel). 2019;8(2):55.Mgbeahuruike E. E. et al. Antimicrobial and synergistic effects of commercial piperine and piperlongumine in combination with conventional antimicrobials // Antibiotics (Basel). 2019. Vol. 8 (2). P. 55.Nagendran Tharmalingam, Sa-Hyun Kim, Min Parket al. Inhibitory effect of piperine on Helicobacter pylori growth and adhesion to gastric adenocarcinoma cells. Infectious Agents and Cancer. 2014;9(1):43–45.Nagendran Tharmalingam, Sa-Hyun Kim, Min Parket al. Inhibitory effect of piperine on Helicobacter pylori growth and adhesion to gastric adenocarcinoma cells // Infect. Agent. Cancer. 2014. Vol. 9 (1). P. 43–45.Amit Kumar Tripathi, Anup Kumar Ray, Sunil Kumar Mishra. Molecular and pharmacological aspects of piperine as a potential molecule for disease prevention and management: evidence from clinical trials. Beni-Suef University Journal of Basic and Applied Sciences. 2022;11(1):16.Amit Kumar Tripathi, Anup Kumar Ray, Sunil Kumar Mishra. Molecular and pharmacological aspects of piperine as a potential molecule for disease prevention and management: evidence from clinical trials // Beni-Suef Univ. J. Basic. Appl. Sci. 2022. Vol. 11 (1). P. 16.Somma A., Canè C., Rotondo N. et al. A comparative study of the inhibitory action of berberine derivatives on the recombinant protein FtsZ of E. coli. International Journal of Molecular Sciences. 2023;24(6):5674.Somma A., Canè C., Rotondo N. et al. A comparative study of the inhibitory action of berberine derivatives on the recombinant protein FtsZ of E. coli // Int. J. Mol. Sci. 2023. Vol. 24 (6). P 5674.Soltani R., Fazeli H. et al. Evaluation of the synergistic effect of Tomatidine with several antibiotics against standard and clinical isolates of Staphylococcus aureus, enterococcus faecalis, Pseudomonas aeruginosa and Escherichia coli. Iranian Journal of Pharmaceutical Research. 2017;16(1):290–296.Soltani R., Fazeli H. et al.Evaluation of the synergistic effect of Tomatidine with several antibiotics against standard and clinical isolates of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa and Escherichia coli. // Iran J. Pharm. Res. 2017. Vol. 16 (1). P. 290–296.Siriyong T. Conessine, as resistance-modifying agents against extensively drug-resistant Acinetobacter baumannii. Microbial Drug Resistance. 2022;(22):273–282.Siriyong T. Conessine, as resistance-modifying agents against extensively drug-resistant Acinetobacter baumannii // Microb. Drug Resist. 2022. N22. P. 273–282.Jeong Yoon Kim, Ju Yeon Kim, Jae Yeon Park et al. Synergistic bactericidal effects of carvone and β-lactams against Xanthomonas campestris pv. vesicatoria. Applied Biological Chemistry. 2023;(66):45–58.Jeong Yoon Kim, Ju Yeon Kim, Jae Yeon Park et al. Synergistic bactericidal effects of carvone and β-lactams against Xanthomonas campestris pv. vesicatoria // Appl. Biol. Chem. 2023. N66. P. 45–58.Althunibat O. Y., Qaralleh H., Al-Dalin S.Y.A. et al. Effect of thymol and carvacrol, the major components of Thymus capitatus on the growth of Pseudomonas aeruginosa. Journal of Pure and Applied Microbiology. 2016;(10):367–374.Althunibat O. Y., Qaralleh H., Al-Dalin S.Y.A. et al. Effect of thymol and carvacrol, the major components of Thymus capitatus on the growth of Pseudomonas aeruginosa // J. Pure Appl. Microbiol. 2016. N10. P. 367–374.Klancnik A., Sikic M., Smole M. S. Jejuni planktonic and biofilm cells, mediated via the CmeABC efflux pump. Journal of Applied Microbiology. 2017;(122):65–77.Klancnik A., Sikic M., Smole M. S. Jejuni planktonic and biofilm cells, mediated via the CmeABC efflux pump // J. Appl. Microbiol. 2017. N122. P. 65–77.Vestergaard M. Antibacterial and antifungal properties of resveratrol. International Journal of Antimicrobial Agents. 2019;(53):716–723.Vestergaard M. Antibacterial and antifungal properties of resveratrol // Int. J. Antimicrob. Agents. 2019. N53. P .716–723.Hotra A., Manuel S., Biucovic G. et al. Deletion of a unique loop in the mycobacterial F-ATP synthase γ subunit sheds light on its inhibitory role in ATP hydrolysis-driven H(+) pumping. FEBS Journal. 2016;283(10):1947–1961.Hotra A., Manuel S., Biucovic G. et al. Deletion of a unique loop in the mycobacterial F-ATP synthase γ subunit sheds light on its inhibitory role in ATP hydrolysis-driven H+ pumping // FEBS J. 2016. Vol. 283 (10). P. 1947–1961.Zou D., Xie K., Wang H., Chen Y., Xie M. Inhibitory effects of Biochanin A on the efflux pump of methicillin-resistant Staphylococcus aureus (MRSA). Wei Sheng Wu Xue Bao. 2014;54(10):1204–1211.Zou D., Xie K., Wang H., Chen Y., Xie M. Inhibitory effects of Biochanin A on the efflux pump of methicillin-resistant Staphylococcus aureus (MRSA) // Wei Sheng Wu Xue Bao. 2014. Vol. 54 (10). P. 1204–1211.Kai-Xuan Hu., Xin-Chi Shi., Dong Xu et al. Antibacterial mechanism of Biochanin A and its efficacy for the control of Xanthomonas axonopodis pv. glycines in soybean. Pest Management Science. 2021;77(4):1668–1673.Kai-Xuan Hu, Xin-Chi Shi, Dong Xu et al. Antibacterial mechanism of Biochanin A and its efficacy for the control of Xanthomonas axonopodis pv. glycines in soybean // Pest Manag. Sci. 2021. Vol. 77 (4). P. 1668–1673.Hanski L., Genina N., Uvell H. et al. Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation. PLoS ONE. 2014;9(12). e115115.Hanski L., Genina N., Uvell H. et al. Inhibitory activity of the isoflavone Biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation // PLoS ONE. 2014. Vol. 9 (12). e115115.Holler J. G., Christensen S. B., Slotved H. C. et al. Novel inhibitory activity of the Staphylococcus aureus NorA efflux pump by a kaempferol rhamnoside isolated from Persea lingue Nees. Journal of Antimicrobial Chemotherapy. 2012;67(5):1138–1144.Holler J. G., Christensen S. B., Slotved H. C. et al. Novel inhibitory activity of the Staphylococcus aureus NorA efflux pump by a kaempferol rhamnoside isolated from Persea lingue Nees // J. Antimicrob. Chemother. 2012. Vol. 67 (5). P. 1138–1144.